logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

Inovio Received $71 Million in Funding from the U.S. Department of Defense

Inovio Received US DoD Funding for CELLECTRA® 3PSP Smart Device Inovio ( INO ) announced today it has received $71 million in funding from the U.S. Department of Defense (DoD) to support the large-scale manufacture of the company's proprietary CELLECTRA®...

Read More

June 23, 2020

0

Gilead Sciences CAR-T Cell Yescarta Became the First and Only FDA Approved Treatment for Patients with Relapsed or Refractory Indolent Follicular Lymphoma

Gilead Sciences Yescarta for Relapsed or Refractory Indolent Follicula Lymphoma If Kite Pharma - a Gilead Sciences ( GILD ) company, had been acquired by any firm other than Gilead the stock would have gained at least 20% because of...

Read More

June 16, 2021

0

The COVID-19 Vaccines' Developing Firms' Bizarre Evaluations

Novel Coronavirus Vaccines and Wall Street Vaccines against novel coronavirus are recognized now as the only way to return disrupted human lives back to normal. Vaccines have become the most important topic for Wall Street’s investors and analysts especially at...

Read More

June 26, 2020

0

Denali Therapeutics: Positive Clinical Results and Regulatory Progress for Development Programs in ALS. See Also: NTLA Tumbling Today

Denali Therapeutics News Denali Therapeutics ( DNLI ) -  a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier ( BBB ) for neurodegenerative diseases.  Denali pursues new treatments by rigorously assessing genetically validated...

Read More

October 8, 2021

0

An FDA Approval for Blueprint Medicines. See Also: An Important Presentation from IVERIC Bio

Inferior ways used to evaluate clinical-stage biotech firms are those that ignore the sciences, the technologies and the promising results from the products in clinical trials. It reached a stage where assessors are even ignoring the value of the approval...

Read More

June 18, 2021

0

Auris Medical Holding Ltd has Encouraging Results Addressing the Unmet Needs of ATLL

Auris Medical Holding Ltd OligoPhore TM Technology for ATLL Auris Medical Holding Ltd. ( EARS ) is a company focusing on addressing unmet medical needs through RNA therapeutics for allergies, viral infection protection and inner ear therapeutics. The firm has...

Read More

June 21, 2021

0

Regenxbio Good News About RGX-314 for Diabetic Retinopathy

Regenxbio Announced Data from Phase 2 ALTITUDE Trial of RGX-314 for DR Regenxbio ( RGNX ) announced initial data from the ongoing Phase 2 ALTITUDE™ trial of RGX-314 for the treatment of diabetic retinopathy ( DR ) without center-involved diabetic...

Read More

October 11, 2021

0

Intellia Therapeutics and SparingVision Strategic Collaboration to Develop Novel Ocular Therapies. See Also: Crispr Therapeutics’ News is Good, Not Bad

Intellia Therapeutics and SparingVision Collaboration Intellia Therapeutics ( NTLA ) and SparingVision - a genomic medicine company developing vision saving treatments for ocular diseases, announced a strategic collaboration to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of...

Read More

October 14, 2021

0

We Are Not Yet in Bizarro World

Unclear Reasoning for the Inovio Selloff Though Inovio ( INO ) announced positive interim clinical data of INO-4800 (its vaccine candidate against novel coronavirus (SARS-CoV-2)) from the first of two Phase 1 clinical trial cohorts, the stock still fell around...

Read More

June 30, 2020

0

Prohost Biotech's Decision About Akero Therapeutics

Akero Therapeutics Today we posted good news from Akero Therapeutics ( AKRO ) under News & Comments . The news was about results from Phase 2a BALANCED study of the firm’s product efruxifermin (EFX), for patients with nonalcoholic steatohepatitis (...

Read More

July 1, 2020

0

  • Previous
  • 1
  • 2
  • ...
  • 25
  • 26
  • 27
  • ...
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy